Abstract
Tandem autologous transplants are generally the preferred therapy for newly diagnosed intermediate- and high-risk myeloma patients. More Jehovah’s Witnesses (JW) are receiving single autologous peripheral blood stem cell transplants (PBSCTs). However, tandem autologous transplants have not been reported in JW patients. We performed a retrospective study of 54 patients, including four JW patients who received tandem autologous transplants between August 2000 and January 2017 and the last 50 consecutive tandem autologous transplants performed between August 2014 and August 2016. The bleeding complications, number, and cost of transfusions of blood products were compared. The median number of CD34 cells infused in non-JW patients was 8.16 million cells/kg versus 9.44 million cells/kg in JW patients. During the first 30 days, one JW experienced Grade III pulmonary hemorrhage, while none of the non-JW patients had a Grade III or higher bleeding problem. After tandem autologous transplants, complete remission was achieved in 88% of non-JW, compared with 75% in JW patients. In the first 30 days post-transplant, median platelet and packed red blood cell (PRBC) transfusions in non-JW patients was 2 (range: 0–40) and 1 (range: 0–11), respectively. Total cost of PRBC and platelet transfusions for the 50 non-JW was $214,664 (average $2147/transplant). Tandem autologous transplants can thus be performed safely without a single blood transfusion.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bodnaruk ZM, Wong CJ, Thomas MJ. Meeting the clinical challenge of chare for Jehovah’s Witnesses. Transfus Med Rev. 2004;18:105–16.
Brown NM, Matthews B, Ford PA. Treatment of a Jehovah’s Witness using a transfusion-free autologous stem cell transplant protocol. Community Oncol. 2006;3:776–80.
Cuirea S, Beri R, Dobogai L, Chunduri S, Mahmud N, Rondelli D, et al. The use of blood conservation methods in addition to erythropoietin allows myeloablative allogeneic stem cell transplantation without the use of blood products [letter]. Bone Marrow Transplant. 2006;37:325–7.
Ballen KK, Becker PS, Yeap BY, Matthews B, Henry DH, Ford PA. Autologous stem-cell transplantation can be performed safely without the use of blood-product support. J Clin Oncol. 2005;22:4087–94.
Ronchetti AM, Isnard F, Buffet M, Coman T, Gorin NC, Coppo P, et al. Dexamethasone, cisplatin, doxorubicin, cyclophosphamide and etoposide (DPACE) is an effective salvage regimen for multiple myeloma refractory to novel agents. Leuk Lymphoma. 2013;54:1117–9.
Nadiminti K, Singh Abbi KK, Mott SL, Dozeman L, Tricot A, Schultz A, Behrends S, Zhan F, Tricot G. VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma. Onco Targets Ther. 2017;10:217–26.
Frere P, Hermanne JP, Debouge MH, Fillet G, Beguin Y. Changing pattern of bacterial susceptibility to antibiotics in hematopoietic stem cell transplant patients. Bone Marrow Transplant. 2002;29:589–94.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.
Kariyawasan CC, Hughes DA, Jayatillake MM, Mehta AB. Multiple myeloma: causes and consequences of delay in diagnosis. QJM. 2007;100:635–40.
Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer. 2011;105:1684–92.
Attal M, Horousseau J, Facon T, Guilhot F, Doyen C, Fuzibet J, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349:2495–502.
Dispenzieri A. Myeloma: management of the newly diagnosed high-risk patient. Hematology. 2016;494:485–94.
Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J. Curing myeloma at last: defining criteria and providing the evidence. Blood. 2014;124:3043–51.
Rogers DM, Crookston KP. The approach to the patient who refuses blood transfusion. Transfusion. 2006;46:1471–7.
Rodriquez MH. [Bloodless medicine (article in Spanish)]. Rev Med Inst Mex Sequro Soc. 2005;43:229–35.
Shander A, Javidrooz M, Perelman S, Puzio T, Lobel G. From bloodless surgery to patient blood management. Mt Sinai J Med. 2012;79:56–65.
Frank SM, Wick SC, Dezern AE, Ness PM, Wasey JO, Pippa AC, et al. Risk-adjusted clinical outcomes in patients enrolled in a bloodless program. Transfusion. 2014;54 (10 pt 2):2668–77.
Jabbour N, Gagandeep S, Mateo R, Sher L, Strum E, Donovan J, et al. Live donor liver transplantation without blood products: strategies developed for Jehovah’s Witnesses offer broad application. Ann Surg. 2004;240:350–7.
Jabbour N, Gagandeep S, Meteo R, Sher L, Genyk Y, Selby R. Transfusion free surgery: single institution experience of 27 consecutive liver transplants in Jehovah’s Witnesses. J Am Coll Surg. 2005;201:412–7.
Boggi U, Vistoli F, Del Chiaro M, Croce C, Signori S, Marchetti P, et al. Kidney and pancreas transplants in Jehovah’s witnesses: ethical and practical implications. Transplant Proc. 2004;36:601–2.
Laszio D, Agazzi A, Goldhirsch A, Cinieri S, Bertolini F, Rabascio C, et al. Tailored therapy of adult acute leukaemia in Jehovah’s Witnesses: unjustified reluctance to treat. Eur J Haematol. 2004;72:264–7.
Brown NM, Kim SY, Ford PA. Autologous stem cell transplants in Jehovah’s Witnesses [letter]. Bone Marrow Transplant. 2009;44:391–2.
Ford PA, Grant SJ, Mick R, Keck G. Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah’s Witnesses. J Clin Oncol. 2015;33:1674–9.
Schmitt S, Mailaender V, Egerer G, Leo A, Becker S, Reinhardt P, et al. Successful autologous peripheral blood stem cell transplantation in a Jehovah’s Witness with multiple myeloma: review of literature and recommendations for high-dose chemotherapy without support of allogeneic blood products. Int J Hematol. 2008;87:289–97.
Wandt H, Schaefer-Eckhart K, Wilhelm M. Two allogeneic hematopoietic stem cell transplantations without the use of blood-product support. Haematologica. 2005;90:1292–4.
Zanz T, Dohner H, Bunies D. Transfusion-free reduced-intensity conditioned allogeneic stem cell transplantation in a Jehovah’s Witness. Bone Marrow Transplant. 2003;32:437–8.
Mazza P, Prudenzana A, Amurri B, Palazzo G, Pisapia G, Stani L, et al. Myeloablative therapy and bone marrow transplantation in Jehovah’s Witnesses with malignancies: single center experience. Bone Marrow Transplant. 2003;32:433–6.
Winslow RM. New frontiers in transfusion medicine. American Association of Blood Banks Teleconference 1995.
Biopure Hemopure. Pharmaceutical approval monthly. F-D-C Rep. 2003;8:6.
Acknowledgements
We acknowledge the nurses in the Clinical Cancer Center, specifically Sonya Behrends, Stephanie Palmer, and Jacque Gingerich, for their outstanding patient care. They would also like to acknowledge Jillna Patel for her excellent administrative assistance in preparing this manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Khan, R., Mott, S.L., Schultz, A. et al. Bloodless tandem autologous transplant in Jehovah’s Witness patients. Bone Marrow Transplant 53, 1428–1433 (2018). https://doi.org/10.1038/s41409-018-0132-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-018-0132-6
This article is cited by
-
Safety of bloodless autologous stem cell transplantation in Jehovah's Witness patients
Bone Marrow Transplantation (2020)